Small Cell Lung Carcinoma Clinical Trial
Official title:
A Multicenter Phase II Trial of Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in Homologous Recombination Deficiency (HRD) Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05882058 -
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
|
Phase 2 | |
| Terminated |
NCT03963414 -
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
|
Phase 1 | |
| Active, not recruiting |
NCT04358237 -
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
|
Phase 1/Phase 2 | |
| Completed |
NCT02874664 -
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT02397733 -
Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)
|
N/A | |
| Recruiting |
NCT01977235 -
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00759824 -
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
|
Phase 2 | |
| Active, not recruiting |
NCT03568097 -
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02876081 -
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
|
Phase 2 | |
| Recruiting |
NCT06247605 -
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04996771 -
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03662074 -
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03232593 -
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
|
||
| Completed |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT01574300 -
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
||
| Recruiting |
NCT06131840 -
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05683977 -
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
|
||
| Recruiting |
NCT04620837 -
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT05329623 -
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
|
Phase 1 | |
| Active, not recruiting |
NCT04902872 -
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
|
Phase 1/Phase 2 |